Pharmacomicrobiomics: Exploiting the Drug-Microbiota Interactions in Antihypertensive Treatment.
Pharmacomicrobiomics: Exploiting the Drug-Microbiota Interactions in Antihypertensive Treatment.
复制标题
DOI：
10.3389/fmed.2021.742394
复制
发表时间：
2021
影响因子：
3.9
通讯作者：
Luo JQ
中科院分区：
文献类型：
--
作者：
Chen HQ;Gong JY;Xing K;Liu MZ;Ren H;Luo JQ
高血压是心血管疾病的主要风险因素，可能会缩短预期寿命。由于降压药的广泛使用，高血压患者在过去的几十年里改善了对血压的控制。然而，对于相当一部分人口来说，这些药物仍然不能显著改善他们的症状。为了探索背后的原因，药物微生物学通过研究肠道微生物区系与降压药物之间的双向相互作用，为高血压的药物治疗提供了独特的见解。本文综述了降压药物与肠道微生物群的关系，包括药物药代动力学和肠道微生物区系组成的变化。此外，我们强调了我们目前对降压药-微生物区系相互作用的了解如何开发基于肠道微生物区系的疾病管理个性化方法，包括抗高血压反应生物标记物、微生物靶向治疗、益生菌治疗。最终，更好地了解药物微生物制剂在高血压治疗中的作用，将为指导临床合理用药和个体化用药提供重要信息。
Hypertension is a leading risk factor for cardiovascular diseases and can reduce life expectancy. Owing to the widespread use of antihypertensive drugs, patients with hypertension have improved blood pressure control over the past few decades. However, for a considerable part of the population, these drugs still cannot significantly improve their symptoms. In order to explore the reasons behind, pharmacomicrobiomics provide unique insights into the drug treatment of hypertension by investigating the effect of bidirectional interaction between gut microbiota and antihypertensive drugs. This review discusses the relationship between antihypertensive drugs and the gut microbiome, including changes in drug pharmacokinetics and gut microbiota composition. In addition, we highlight how our current knowledge of antihypertensive drug-microbiota interactions to develop gut microbiota-based personalized ways for disease management, including antihypertensive response biomarker, microbial-targeted therapies, probiotics therapy. Ultimately, a better understanding of the impact of pharmacomicrobiomics in the treatment of hypertension will provide important information for guiding rational clinical use and individualized use.
登录
查看更多内容
DOI：
10.1161/hyp.0000000000000084
发表时间：
2018-11
期刊：
Hypertension (Dallas, Tex. : 1979)
影响因子：
--
作者：
Carey RM;Calhoun DA;Bakris GL;Brook RD;Daugherty SL;Dennison-Himmelfarb CR;Egan BM;Flack JM;Gidding SS;Judd E;Lackland DT;Laffer CL;Newton-Cheh C;Smith SM;Taler SJ;Textor SC;Turan TN;White WB;American Heart Association Professional/Public Education and Publications Committee of the Council on Hypertension; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Genomic and Precision Medicine; Council on Peripheral Vascular Disease; Council on Quality of Care and Outcomes Research; and Stroke Council
通讯作者：
American Heart Association Professional/Public Education and Publications Committee of the Council on Hypertension; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Genomic and Precision Medicine; Council on Peripheral Vascular Disease; Council on Quality of Care and Outcomes Research; and Stroke Council
影响因子：
4.7
作者：
Chang, B. J.;Park, S. U.;Chang, D. K.
通讯作者：
Chang, D. K.
影响因子：
6.7
作者：
BOYD, RA;CHIN, SK;GIACOMINI, KM
通讯作者：
GIACOMINI, KM
DOI：
10.1073/pnas.1215689109
发表时间：
2012-12-26
影响因子：
11.1
作者：
Craciun, Smaranda;Balskus, Emily P.
通讯作者：
Balskus, Emily P.
影响因子：
6.7
作者：
Birer C;Wright ES
通讯作者：
Wright ES